Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ Model

Evaluation of the Anticaries Efficacy of Various Dentifrice Formulations Using an In-situ Model

The primary objective is to compare the remineralization and demineralization inhibition potential of early subsurface carious lesions in enamel in situ after rinsing with six different aqueous slurries of toothpaste formulations.

Study Overview

• Status: Completed
• Conditions: Caries
• Intervention / Treatment: Drug: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice; Drug: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice; Drug: Toms of Maine 0 ppm Fluoride Dentifrice; Drug: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice; Drug: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice; Drug: 1100 ppm (0.454% Stannous fluoride) Dentifrice

• Study Type: Interventional
• Enrollment (Actual): 12
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Australia
  • Melbourne, Australia
    • University of Melbourne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Be 18-75 years of age.
• Provide written informed consent prior to participation and be given a signed copy of the informed consent form.
• Be in good general health based on medical/dental history and oral exam.
• Have no history of adverse or allergic reactions to tin or tin-containing products.
• Agree not to participate in any other oral study for the study duration.
• Have a reasonable functional dentition as determined by the oral examiner and sufficient teeth to support the fabricated dental appliance.
• Be willing to participate in the study, able to follow the study directions, successfully tolerate/perform all study procedures, and willing to return for all specified visits at their appointed time.
• Be willing to refrain from using non-study dentifrice, mouth rinse, chewing gum, and other non-study oral care products during the study.
• Be willing to postpone all elective dental procedures until the study has been completed.
• Be willing to refrain from using calcium chews while using the test products.
• Be willing and able to refrain from wearing a nightguard (occlusal splint) for the entire course of the study (for nightguard wearers only).
• Ability to understand, and ability to read and sign, the informed consent form.
• Have at least 22 natural teeth.
• Have a gum-stimulated whole salivary flow rate ≥ 1.0 ml/minute and unstimulated whole salivary flow rate ≥ 0.2 ml/minute.

Exclusion Criteria:

-

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice	Drug: Oral-B 1450 ppm Fluoride (1.16% sodium monofluorophosphate) Dentifrice; Each subject will use this product during one of the six treatment periods in the crossover study design.
Active Comparator: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice	Drug: Colgate 1450 ppm Fluoride (1.16% sodium monofluorophosphate)Dentifrice; Each subject will use this product during one of the six treatment periods in the crossover study design.
Sham Comparator: Toms of Maine 0 ppm Fluoride Dentifrice	Drug: Toms of Maine 0 ppm Fluoride Dentifrice; Each subject will use this product during one of the six treatment periods in the crossover study design.
Active Comparator: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice	Drug: Colgate 1450 ppm Fluoride (1.1% sodium monofluorophosphate) Dentifrice; Each subject will use this product during one of the six treatment periods in the crossover study design.
Active Comparator: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice	Drug: 1500 ppm MFP/CaCO3 1.16% sodium monofluorophosphate) Dentifrice; Each subject will use this product during one of the six treatment periods in the crossover study design.
Active Comparator: 1100 ppm (0.454% Stannous fluoride) Dentifrice	Drug: 1100 ppm (0.454% Stannous fluoride) Dentifrice; Each subject will use this product during one of the six treatment periods in the crossover study design.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mineral Density	The percent mineral profile of each enamel/dentinel slab's demineralized control and remineralized/treated lesion, obtained from the microdensitometry analysis, will be compared with the median sound enamel percent mineral profile of the same section. A negative value indicates mineral has been lost and, therefore, the lesion has progressed, whereas a positive value indicates mineral has been gained and, therefore, the lesion has regressed.	14 days
Scanning Electron Microscopy (SEM)	SEM imaging and SEM-EDS analysis will be conducted on TMR sections and whole sections of dentine lesions treated in situ to assess the occlusion of dentine tubules and distribution of elements within the lesions following the experiment.	14 days

Collaborators and Investigators

• Sponsor: Procter and Gamble

Study record dates

Study Major Dates

• Study Start (Actual): July 31, 2023
• Primary Completion (Actual): December 11, 2023
• Study Completion (Actual): December 11, 2023

Study Registration Dates

• First Submitted: November 14, 2023
• First Submitted That Met QC Criteria: November 14, 2023
• First Posted (Actual): November 20, 2023

Study Record Updates

• Last Update Posted (Estimated): February 29, 2024
• Last Update Submitted That Met QC Criteria: February 27, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Anti-Infective Agents, Local; Anti-Infective Agents; Protective Agents; Cariostatic Agents; Listerine; Fluorides; Sodium Fluoride; Tin Fluorides; Fluorophosphate
• Other Study ID Numbers: 2022085

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No